Related Experiment Videos
[Role of clopidogrel in acute coronary syndromes without ST-segment elevation]
Attilio Maseri1, Domenico Cianflone, Alberto Margonato
1Dipartimento di Malattie Cardiovascolari Università Vita e Salute San Raffaele Istituto Scientifico H San Raffaele Via Olgettina, 60 20132 Milano.
Insights
Platelets are key in acute coronary syndromes (ACS). Modulating platelet aggregation with agents like clopidogrel offers effective treatment strategies for preventing cardiovascular events in ACS patients.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Acute coronary syndromes (ACS), including unstable angina and non-ST-segment elevation myocardial infarction, involve minimal myocardial damage but can precede major infarction.
- Platelet-rich coronary thrombi are central to ACS pathogenesis, representing a critical therapeutic target.
- Understanding thrombotic stimuli and prothrombotic factors in ACS is crucial for effective management.
Purpose of the Study:
- To review the mechanisms of instability in ACS.
- To analyze therapeutic strategies for ACS, focusing on antiplatelet agents.
- To evaluate the role of clopidogrel in preventing cardiovascular events in ACS.
Main Methods:
- Analysis of coronary thrombus composition in ACS patients.
- Review of platelet adhesion and aggregation mechanisms.
- Examination of clopidogrel's characteristics and efficacy.
- Assessment of therapeutic strategies and adjunctive clopidogrel therapy.
Main Results:
- Platelets are the primary component of coronary thrombi in ACS.
- Modulating platelet aggregation is an effective therapeutic strategy.
- Clopidogrel demonstrates efficacy in preventing cardiovascular events in ACS.
Conclusions:
- Platelet aggregation modulation is a key target in ACS management.
- Clopidogrel represents a valuable therapeutic option for ACS patients.
- Adjunctive clopidogrel therapy holds significant implications for treating and preventing cardiovascular events in ACS.
Abstract:
Unstable angina and no ST-segment elevation myocardial infarction are acute coronary syndromes (ACS) typically characterized by minimal or little myocardial damage, but often heralding "classical" infarction or coronary death in the short or medium term. Coronary thrombi, mainly composed by platelets, are the major pathogenetic component of ACS and an effective therapeutic target. The hemostatic balance can be shifted towards an antithrombotic state in the clinical setting. Although the thrombogenic stimuli acting in each individual patient, their intensity as well as the prothrombotic factors that may contribute to an inappropriate thrombus growth, remain largely unknown. To this purpose the modulation of platelet aggregation is a particularly effective and practical therapeutic target. The availability of a new antiplatelet agent, clopidogrel, with a proven efficacy in the prevention of cardiovascular events, suggests the opportunity of reviewing the mechanisms of instability and the therapeutic strategies in patients with ACS. In this review we analyze: 1) the composition of coronary thrombi in patients with ACS, 2) the mechanisms of thrombus development and growth, 3) the mechanisms of platelet adhesion and aggregation, 4) the characteristics of clopidogrel, 5) the efficacy of the various therapeutic strategies, 6) the possible implications of the adjunctive therapy with clopidogrel for the treatment and prevention of cardiovascular events in ACS with no ST-segment elevation.